in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
49<br />
❚ melaton<strong>in</strong><br />
<strong>Cerep</strong><br />
services<br />
MT 1 (ML 1A ) - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 1538<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
ExpresS Profile<br />
High-throughput profile<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
[ 125 I]2-iodomelaton<strong>in</strong> (0.01 nM)<br />
0.04 nM<br />
melaton<strong>in</strong> (1 µM)<br />
melaton<strong>in</strong> (IC 50 : 0.16 nM)<br />
Witt-Enderby, P.A. and Dubocovitch, M.L. (1996) Mol. Pharm., 50: 166-174.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4<br />
log [drug] (M)<br />
melaton<strong>in</strong><br />
2-iodomelaton<strong>in</strong><br />
6-chloromelaton<strong>in</strong><br />
luz<strong>in</strong>dole<br />
<br />
Receptors<br />
[GPCRs]<br />
Ion<br />
channels<br />
MT 1 (ML 1A )<br />
cellul ar<br />
Ref. 2498 Agonist effect<br />
Ref. 2500 Antagonist effect<br />
Q 3 weeks<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product impedance<br />
Detection method cellular dielectric spectroscopy<br />
Agonist effect Control melaton<strong>in</strong> (10 nM)<br />
Reference melaton<strong>in</strong> (EC 50 : 0.22 nM)<br />
Antagonist effect Stimulant melaton<strong>in</strong> (1 nM)<br />
Reference luz<strong>in</strong>dole (IC 50 : 680 nM)<br />
Brown<strong>in</strong>g, C. et al. (2000) Br. J. Pharmacol., 129: 877-886.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.1%<br />
Transporters<br />
K<strong>in</strong>ases<br />
MT 2 (ML 1B ) - agonist radioligand<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Ligand<br />
[ 125 I]2-iodomelaton<strong>in</strong> (0.05 nM)<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Kd<br />
0.085 nM<br />
Ref. 1687<br />
Non specific melaton<strong>in</strong> (1 µM)<br />
Q 3 weeks<br />
Reference melaton<strong>in</strong> (IC 50 : 0.18 nM)<br />
Included <strong>in</strong>:<br />
Organ safety profile<br />
Beresford, I.J.M. et al. (1998) J. Pharmacol. Exp. Ther., 285: 1239-1245.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
<br />
<br />
<br />
<br />
<br />
100<br />
<br />
<br />
<br />
50 <br />
<br />
<br />
melaton<strong>in</strong><br />
2-iodomelaton<strong>in</strong><br />
4-P-PDOT<br />
0<br />
luz<strong>in</strong>dole<br />
-13 -12 -11 -10 -9 -8 -7 -6<br />
log [drug] (M)<br />
Epigenetic &<br />
DNA-related<br />
enzymes<br />
Other<br />
enzymes<br />
MT 2 (ML 1B )<br />
cellul ar<br />
Ref. 2092 Agonist effect<br />
Ref. 2100 Antagonist effect<br />
Q 3 weeks<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product cAMP<br />
Detection method HTRF<br />
Agonist effect Control melaton<strong>in</strong> (1 µM)<br />
Reference melaton<strong>in</strong> (EC 50 : 0.25 nM)<br />
Antagonist effect Stimulant melaton<strong>in</strong> (10 nM)<br />
Reference unavailable<br />
Beresford, I.J.M. et al. (1998) J. Pharmacol. Exp. Ther., 285: 1239-1245.<br />
cAMP modulation (% of control)<br />
100<br />
50<br />
0<br />
log [agonist] (M)<br />
melaton<strong>in</strong><br />
2-iodomelaton<strong>in</strong><br />
GR 135531<br />
IIK7<br />
[Solvent] must be kept ≤ 0.3%<br />
-11 -10<br />
-12 -11<br />
-10 -9 -8 -7 -6<br />
-9 -8 -7 -6 -5 -4<br />
antagonist effect:<br />
no graph available<br />
❚ See other Melaton<strong>in</strong> assays, page 89<br />
Specialized<br />
cellular<br />
assays<br />
Standard<br />
profiles<br />
-12 -11<br />
-10 -9 -8 -7<br />
❚ motil<strong>in</strong><br />
-12 -11<br />
-12 -11<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7 -6 -5<br />
-11 -10<br />
-9 -8 -7 -6 -5 -4<br />
Test<strong>in</strong>g<br />
conditions<br />
motil<strong>in</strong> - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0470<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
BioPr<strong>in</strong>t ® profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
[ 125 I]motil<strong>in</strong> (0.05 nM)<br />
0.26 nM<br />
[Nleu 13 ]-motil<strong>in</strong> (1 µM)<br />
[Nleu 13 ]-motil<strong>in</strong> (IC 50 : 1.4 nM)<br />
Feighner, S.D. et al. (1999) Science, 284: 2184-2188.<br />
-9 -8 -7 -6 -5<br />
-10 -4<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2<br />
log [drug] (M)<br />
● [Nleu 13 ]-motil<strong>in</strong><br />
■ motil<strong>in</strong><br />
▲ erythromic<strong>in</strong><br />
Order<strong>in</strong>g<br />
<strong>in</strong>formation<br />
Assay list<br />
& <strong>in</strong>dex